Antibacterial Agents TRIZ Cases

Seven novel bacteriophages kill C. difficile ribotypes, bypassing antibiotic resistance.

Protamine sulfate combined with silver nanoparticles disrupts biofilm matrices to reduce microbial resistance and toxicity in wound care applications.

Cationic steroidal antimicrobials bypass spore impermeability to destroy DNA, eliminating reliance on toxic oxidizing agents.

A pharmaceutical composition maintains active ingredient solubility using a composite polymer system.

Fused bicycloheterocycle substituted azabicyclic compounds selectively modulate alpha7 and alpha4beta2 nicotinic acetylcholine receptors.

Antibody targeting LPS O11 antigen overcomes multidrug resistance in Pseudomonas aeruginosa via opsonophagocytic killing.

Optimized temporin-SHf analogs boost antimicrobial activity against resistant bacteria while lowering cytotoxicity and production costs.

Engineered lactic acid bacteria coaggregate with Streptococcus pyogenes to block host cell adhesion.

Low molecular weight dextran sulfate extends urokinase activity for 28 days, preventing thrombosis in implantable catheters.

Multivalent synthetic compounds with pseudopeptide units target surface nucleolin to inhibit tumour growth and angiogenesis.

Formula I compound selectively targets resistant Neisseria strains, preventing colonization without triggering horizontal gene transfer of resistance.

Nanoparticle compositions encapsulate pharmaceuticals via biodegradable polymers, resolving size distribution limits in particulate carriers.

Antisense oligonucleotides modulate tumor suppressor gene expression by binding to natural antisense transcripts, resolving specificity and delivery challenges.

Carotenoids modulate gut microbiomes by increasing Bifidobacterium counts and reducing pathogenic bacteria.

Therapeutic agents targeting conserved host interaction factors overcome antibiotic resistance and limited serogroup coverage in Neisseria treatments.

Thiadiazolidinone derivatives inhibit protein tyrosine phosphatases, addressing inadequate management of insulin resistance and diabetes.

Deleting B5R, B6R, A56R genes eliminates normal cell toxicity while preserving antitumor efficacy.

Polymyxin compounds with four or more positive charges disrupt kidney cell membrane alignment, reducing nephrotoxicity while retaining antibacterial efficacy.

Bis-indolylmethane adjuvants restore antibiotic effectiveness against resistant pathogens, bypassing lengthy new drug development cycles.

Bacterial aldehyde dehydrogenase converts retinol to retinoic acid in the intestine.

Modified 5-aminolevulinic acid derivatives improve selectivity and efficacy in photodynamic therapy by enhancing cellular uptake.

Chimeric anti-IL-6 antibodies combine murine binding regions with human frameworks to reduce immunogenicity while maintaining therapeutic efficacy.

Modified cyclodextrin reduces preservative binding to maintain antimicrobial activity and injection site toleration.

Talc-filled hydrophobic coatings on microgranules resist alcohol-induced dose dumping to maintain sustained release kinetics.

Benzoxaborole compounds bind KPC-2 enzymes to prevent carbapenem hydrolysis, restoring Meropenem efficacy against Klebsiella pneumoniae infections.

Universal binding of a cross-reactive antibody to the C-terminal TLR2 domain resolves species-specific limitations while preventing septic shock.

Ligand-modified copper oxo-hydroxide nanoparticles release free copper ions through non-stoichiometric carboxylic acid substitution.

Segmented phenytoin scaffold combats drug-resistant microbes by targeting diverse mechanisms to overcome antibiotic resistance.

Pyridinyl sulfoxide compounds inhibit the NAMPT enzyme to induce apoptotic cell death in tumor cells.

A catechol group at the 3-position side chain of Cephem compounds chelates Fe3+ ions to overcome Class B metallo-beta-lactamase resistance.

A detoxified E. coli heat-labile enterotoxin mutant serves as a carrier protein to covalently link polysaccharides via reductive amination.

Live attenuated Ehrlichia canis induces protective immunity without adjuvants.

Carboxylic acid aromatic amides block the Bradykinin B1 receptor, reducing inflammatory cytokines and providing safer chronic pain relief.

Pre-cross-linking stabilizes the polymer against sterilization degradation, enabling sustained antibiotic release while maintaining biocompatibility.

Benzimidazole derivatives achieve high potency and specificity by applying local quality and asymmetry principles to target the enzyme active site.

Ligand-modified ruthenium catalyst reduces residual metal levels and reagent costs during asymmetric oxcarbazepine synthesis for industrial scale.

Segmented biodegradable structures release sequential drug doses to eliminate repeated clinical visits and logistical burdens in rural settings.

A stable antimicrobial propanone compound inhibits odor-causing bacteria in cosmetic formulations.

Modular synthesis with protecting groups resolves the trade-off between enhanced antimicrobial activity and increased manufacturing complexity.

A detection method using single nucleotide polymorphisms in 16S ribosomal RNA genes to identify and classify bacterial species.

Segmented 10-14 amino acid peptides cross the blood-brain barrier to treat neuroinflammatory disorders while simplifying chemical synthesis.

Flagellin mediates cancer treatment by activating innate immunity to delay tumor growth and protect liver tissue from death receptor agonist toxicity.

Bioinformatics identifies novel surface-exposed proteins to reduce time-consuming empirical testing in vaccine development.